PT  - JOURNAL ARTICLE
AU  - Bernard Combe
AU  - Frank Behrens
AU  - Neil McHugh
AU  - Fiona Brock
AU  - Urs Kerkmann
AU  - Blerina Kola
AU  - Gaia Gallo
TI  - Comparison of Etanercept Monotherapy and Combination Therapy with Methotrexate in Psoriatic Arthritis: Results from 2 Clinical Trials
AID  - 10.3899/jrheum.151290
DP  - 2016 May 01
TA  - The Journal of Rheumatology
PG  - jrheum.151290
4099  - http://www.jrheum.org/content/early/2016/04/22/jrheum.151290.short
4100  - http://www.jrheum.org/content/early/2016/04/22/jrheum.151290.full
AB  - Objective To evaluate the clinical/functional outcomes associated with etanercept (ETN) monotherapy versus combination therapy in psoriatic arthritis (PsA). Methods Data from patients with PsA who received ETN alone (n = 322) or combined with methotrexate (MTX; n = 152) for 24 weeks in 2 placebo-controlled clinical trials were summarized across studies. Results Similar proportions of patients in the monotherapy and combination therapy groups achieved the PsA Response Criteria (80% and 83%) and the American College of Rheumatology improvements of 20% (ACR20; both 70%); numerically higher proportions receiving monotherapy achieved ACR50 (55% vs 48%) and ACR70 (35% vs 27%). Little between-group difference was observed in the 28-joint Disease Activity Score with C-reactive protein, the Psoriasis Area and Severity Index, and the Health Assessment Questionnaire–Disability Index improvement. Conclusion ETN with and without MTX provided similar benefits in active PsA.